Khaitan Divya, Sankpal Umesh T, Weksler Babette, Meister Edward A, Romero Ignacio A, Couraud Pierre-Olivier, Ningaraj Nagendra S
Department of Laboratory Oncology Research, Curtis and Elizabeth Anderson Cancer Institute, Hoskins Center for Biomedical Research, Savannah, Georgia 31404, USA.
BMC Cancer. 2009 Jul 29;9:258. doi: 10.1186/1471-2407-9-258.
The prognosis for patients with breast tumor metastases to brain is extremely poor. Identification of prognostic molecular markers of the metastatic process is critical for designing therapeutic modalities for reducing the occurrence of metastasis. Although ubiquitously present in most human organs, large-conductance calcium- and voltage-activated potassium channel (BKCa) channels are significantly upregulated in breast cancer cells. In this study we investigated the role of KCNMA1 gene that encodes for the pore-forming alpha-subunit of BKCa channels in breast cancer metastasis and invasion.
We performed Global exon array to study the expression of KCNMA1 in metastatic breast cancer to brain, compared its expression in primary breast cancer and breast cancers metastatic to other organs, and validated the findings by RT-PCR. Immunohistochemistry was performed to study the expression and localization of BKCa channel protein in primary and metastatic breast cancer tissues and breast cancer cell lines. We performed matrigel invasion, transendothelial migration and membrane potential assays in established lines of normal breast cells (MCF-10A), non-metastatic breast cancer (MCF-7), non-brain metastatic breast cancer cells (MDA-MB-231), and brain-specific metastatic breast cancer cells (MDA-MB-361) to study whether BKCa channel inhibition attenuates breast tumor invasion and metastasis using KCNMA1 knockdown with siRNA and biochemical inhibition with Iberiotoxin (IBTX).
The Global exon array and RT-PCR showed higher KCNMA1 expression in metastatic breast cancer in brain compared to metastatic breast cancers in other organs. Our results clearly show that metastatic breast cancer cells exhibit increased BKCa channel activity, leading to greater invasiveness and transendothelial migration, both of which could be attenuated by blocking KCNMA1.
Determining the relative abundance of BKCa channel expression in breast cancer metastatic to brain and the mechanism of its action in brain metastasis will provide a unique opportunity to identify and differentiate between low grade breast tumors that are at high risk for metastasis from those at low risk for metastasis. This distinction would in turn allow for the appropriate and efficient application of effective treatments while sparing patients with low risk for metastasis from the toxic side effects of chemotherapy.
乳腺肿瘤脑转移患者的预后极差。识别转移过程的预后分子标志物对于设计减少转移发生的治疗方式至关重要。尽管大电导钙和电压激活钾通道(BKCa)在大多数人体器官中普遍存在,但在乳腺癌细胞中显著上调。在本研究中,我们调查了编码BKCa通道孔形成α亚基的KCNMA1基因在乳腺癌转移和侵袭中的作用。
我们进行了全外显子芯片分析以研究KCNMA1在乳腺脑转移癌中的表达,比较其在原发性乳腺癌和转移至其他器官的乳腺癌中的表达,并通过逆转录聚合酶链反应(RT-PCR)验证结果。进行免疫组织化学以研究BKCa通道蛋白在原发性和转移性乳腺癌组织及乳腺癌细胞系中的表达和定位。我们在正常乳腺细胞(MCF-10A)、非转移性乳腺癌(MCF-7)、非脑转移性乳腺癌细胞(MDA-MB-231)和脑特异性转移性乳腺癌细胞(MDA-MB-361)的既定细胞系中进行了基质胶侵袭、跨内皮迁移和膜电位测定,以研究BKCa通道抑制是否使用小干扰RNA(siRNA)敲低KCNMA1和用iberiotoxin(IBTX)进行生化抑制来减弱乳腺肿瘤的侵袭和转移。
全外显子芯片分析和RT-PCR显示,与转移至其他器官的乳腺癌相比,乳腺脑转移癌中KCNMA1表达更高。我们的结果清楚地表明,转移性乳腺癌细胞表现出增加的BKCa通道活性导致更大的侵袭性和跨内皮迁移,两者均可通过阻断KCNMA1来减弱。
确定乳腺脑转移癌中BKCa通道表达的相对丰度及其在脑转移中的作用机制将提供一个独特的机会,以识别和区分低级别乳腺肿瘤中转移风险高的肿瘤与转移风险低的肿瘤。这种区分反过来将允许在避免转移风险低患者遭受化疗毒性副作用的同时,适当且有效地应用有效治疗。